Bombay High Court Quashes NPPA Demands: No Monopoly, DPCO 2013 Limits Authority to Parent Ministries’ Framework

Bombay High Court Quashes NPPA Demands: No Monopoly, DPCO 2013 Limits Authority to Parent Ministries’ Framework

Summary:

In a landmark ruling, the Bombay High Court has clarified that DPCO 2013 price control applies only to scheduled formulations listed in the First Schedule. The Court quashed multiple NPPA demand notices issued by the National Pharmaceutical Pricing Authority for alleged overcharging on non-scheduled formulations, including sustained-release (SR) and modified dosage forms.

The judgment reinforces that under the Drugs (Prices Control) Order, 2013, only explicitly notified formulations are subject to drug price control in India, while non-scheduled drugs fall under price monitoring, not ceiling pricing. This decision provides significant relief to the pharmaceutical industry, reduces regulatory uncertainty, and supports innovation in drug delivery systems without the risk of retrospective NPPA action.

Background of the NPPA Demand Notices

Mumbai, April 14, 2026 - In a landmark Bombay High Court judgment on pharmaceutical pricing in India, that brings major relief to pharmaceutical manufacturers, the Bombay High Court has held that ceiling prices under the Drugs (Prices Control) Order, 2013 (DPCO 2013) can be imposed only on formulations explicitly listed in the First Schedule. The court quashed all demand notices issued by the National Pharmaceutical Pricing Authority (NPPA) seeking to bring unlisted variants - such as sustained-release (SR) or modified-dosage forms - under price control.

The Division Bench of Bombay High Court, delivered the judgment on April 10, 2026, in two writ petitions: M/s. Franco Indian Pharmaceuticals Pvt. Ltd. & Anr. v. Union of India & Ors. and Indian Drug Manufacturers Association v. Ministry of Chemicals and Fertilizers & Ors.

NPPA Overcharging Case

NPPA stand was that once a base drug is scheduled, all its variants - including different delivery mechanisms like SR/CR tablets - automatically fall under price ceilings under drug price control in India.

One such demand against a petitioner exceeded ₹7.88 crore for a sustained-release formulation of Metformin, raising concerns across the pharmaceutical industry in India.

Key Observations by the Bombay High Court

The High Court rejected NPPA’s expansive interpretation, observing that:

1. The absence of a specific formulation from the Schedule “indicates a conscious decision not to subject it to price control under DPCO 2013.

2. Extending ceilings to unlisted variants would render the requirement of specific notifications under drug pricing regulations in India “otiose” (redundant).

3. The Ministry of Chemicals and Fertilizers and Ministry of Health and Family Welfare had issued clarifications stating that innovative/non-conventional dosage forms (SR, CR, etc.) are not covered under drug price control in India unless expressly included.

4. As a subordinate authority, NPPA cannot take a view contrary to the parent ministries’ official stand under pharmaceutical regulatory framework in India.

5. The court allowed both writ petitions and set aside the impugned demand notices in their entirety.

Impact on Pharmaceutical Industry in India

This ruling is a major relief for the pharmaceutical industry and strengthens pharma regulatory compliance in India.

● Confirms that DPCO 2013 price control is formulation-specific

● Reduces litigation and arbitrary NPPA recovery demands

● Encourages innovation in SR, CR, and modified-release formulations

● Provides clarity on drug pricing regulations in India

Conclusion

The judgment marks a significant development in drug price control in India, ensuring that regulatory authorities adhere strictly to statutory provisions.

It brings clarity, reduces uncertainty, and supports a balanced approach between affordability and pharmaceutical innovation.

Read the Full Bombay High Court Judgment on DPCO 2013 and NPPA Demand Notices

Note:
Cases related to Pharmaceuticals are highly technical and knowledge-driven. If you're searching for a drugs and cosmetics lawyer in India, a pharmaceutical lawyer, Mace Corporate Associates is the perfect place. If you are searching for a DPCO Lawyer for overcharging cases or DPCO Compliance, Mace can assist you well. May it be a clinical trial Lawyer or a Medical device lawyer, Mace can be of great and perfect match for Pharmaceutical litigation. Mace has an accomplished track record for Not of Standard Quality Cases, Licensing Cases etc.